Study of TQ-F3083 Capsules in Subjects With Type 2 Diabetes Mellitus

Summary

TQ-F3083 capsule is a new type inhibitor of DPP-IV, which is currently a very effective target for the treatment of type 2 diabetes mellitus at clinical. In addition, it can promote insulin secretion with low potential toxicity, and half-life is shorter than Linagliptin.

Timeline

Start

2020-01-01

Primary completion

2020-06-30

Completion

2020-09-30

Drugs

Indications